|
rs10012
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When we corrected for multiple testing using these statistical tools, three novel associations of NSCLC risk with SNPs in the CYP1B1 (Arg48Gly), COMT (Val158Met) and GSTT2 (Met139Ile) genes were found noteworthy.
|
18258609 |
2008 |
|
rs1001581
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Larger studies that will focus on the role of the rs1001581 and rs2293036 htSNPs and haplotypes for developing NSCLC are needed in the future.
|
20978448 |
2010 |
|
rs10023113
|
|
A |
0.710 |
GeneticVariation |
GWASCAT |
These findings suggest that CAMK2D rs10023113 may be a potentially prognostic marker for overall survival of early-stage NSCLC patients in Chinese population.
|
25145502 |
2015 |
|
rs10023113
|
|
|
0.710 |
GeneticVariation |
BEFREE |
These findings suggest that CAMK2D rs10023113 may be a potentially prognostic marker for overall survival of early-stage NSCLC patients in Chinese population.
|
25145502 |
2015 |
|
rs1005165
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that rs1005165 and rs967591 were significantly associated with NSCLC risk in Chinese non-smoking females.
|
29108262 |
2017 |
|
rs10079250
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These results suggest that TP63 rs7631358 G > A and CSF1R rs10079250 A > G may affect the prognosis of NSCLC in never-smoking females, as well as the risk of lung cancer.
|
28449811 |
2017 |
|
rs1012477
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
|
28177907 |
2017 |
|
rs10165970
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
|
28177907 |
2017 |
|
rs1022059218
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, the constellation of alleles CTLA-4c.49A>G[A]/CT60[G]/CD28c.17+3T>C[T]/ICOSc.1554+4GT(8_15)[>10] increased the risk of NSCLC about 2-fold (p = 0.002).
|
21669243 |
2011 |
|
rs1026411
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, polymorphisms in rs1026411 and rs710886 were observed to have significant associations with susceptibility to non-small cell lung cancer (AG vs. GG: odds ratio [OR]<sup>a</sup> = 0.701, <i>p</i>* = 0.020 and AA+AG vs. GG: OR<sup>a</sup> = 0.711 [superscript "a" refers to OR adjusted by age, gender, and smoking], <i>p</i>* = 0.017 [asterisks "*" refers to <i>p</i> adjusted by age, gender, and smoking] for rs1026411; CT vs. TT: OR<sup>a</sup> = 0.723, <i>p</i>* = 0.047 and CC+CT vs. TT: OR<sup>a</sup> = 0.729, <i>p</i>* = 0.038 for rs710886).
|
31464517 |
2019 |
|
rs1032737355
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, we present a case of a patient with non-small cell lung cancer (NSCLC) harboring 3 uncommon mutations of EGFR-R670W in exon 17 and H833V, and H835L in exon 21, as shown by next-generation sequencing of plasma cell-free DNA.
|
30127622 |
2018 |
|
rs1042489
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After adjusting for age, gender, smoking status, histology, stage, surgical operation, and chemotherapy or radiotherapy status, Cox hazard proportional model suggested that four single nucleotide polymorphisms had statistically significant impacts on NSCLC survival (rs3764383, AG/GG versus AA, hazard ratio [HR] = 0.78, 95% confidence interval [CI]: 0.62-0.99; rs8073069, GG versus CG/CC, HR = 1.76, 95% CI: 1.16-2.67; rs4789551, GG versus AG/AA, HR = 2.04, 95% CI: 1.08-3.86; rs1042489, GG versus AG/AA, HR = 1.37, 95% CI: 1.03-1.83).
|
20881643 |
2010 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study aims to determine the value of codon 72 missense polymorphic variant genotyping, TP53 R72P, as a prognostic factor in NSCLC patients.
|
29286914 |
2018 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We evaluated seven single-nucleotide polymorphisms of six genes CDA Lys27Gln (A/C); CDA C435T; ERCC1 C118T; XRCC3 Thr241Met (C/T); XPD Lys751Gln (A/C); P53 Arg72Pro (G/C), and RRM1 C524T in 192 chemotherapy-naive patients with advanced NSCLC treated with cisplatin/gemcitabine-based regimen by TaqMan probe-based assays with 7300 Real-Time PCR System, using genomic DNA extracted from blood samples.
|
22052224 |
2011 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our results suggest that the genotype of the Arg72Pro polymorphism may modulate the frequency of TP53 mutations in non-small-cell lung cancer.
|
17932356 |
2007 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study investigated whether the functional polymorphisms in P53 pathway genes, P53 Arg72Pro (rs1042522), P73 G4C14-to-A4T14 (rs2273953 and rs1801173), and MDM2 T309G (rs2279744), alone or in combination, affect survival in advanced non-small cell lung cancer (NSCLC) patients.
|
21841506 |
2011 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
|
16499995 |
2006 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In summary, we found that the p53 p. Pro72Arg, MDM2 c.14 + 309T > G and MDM2 c.-461C > G polymorphisms are associated with toxicity risks following platinum-based chemotherapy treatment in advanced NSCLC patients.
|
25482940 |
2014 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The purpose of the study was to investigate whether polymorphisms of p53 codon 72 (Arg72Pro) and MDM2 SNP309 (309T>G) affect p53 expression and the clinical outcome of patients with advanced nonsmall cell lung cancer (NSCLC).
|
18618574 |
2008 |
|
rs1042852
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Samples from 393 patients with NSCLC treated with definitive radiotherapy at a single institution between March 1998 and February 2009 were used to genotype 3 potentially functional SNPs in CBLB (rs1042852 C>T, rs2305035 G>A, and rs7649466 C>G).
|
26732495 |
2016 |
|
rs10429489
|
|
A |
0.700 |
GeneticVariation |
GWASCAT |
Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.
|
31326317 |
2019 |
|
rs1045642
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Using the TaqMan 5' nuclease assay, we examined ERCC1 118, XPD 751 and 312, RRM1 -37C/A, and MDR1 C3435T SNPs in peripheral blood lymphocytes (PBLs) obtained from 62 docetaxel-cisplatin-treated advanced NSCLC patients.
|
15277258 |
2004 |
|
rs1045642
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Our findings suggest that MDR1 2677G-->T/A and 3435C-->T polymorphisms can be used to predict treatment response to VC chemotherapy in NSCLC patients.
|
17851225 |
2008 |
|
rs1045642
|
|
|
0.060 |
GeneticVariation |
BEFREE |
In this study we investigated the potential association of MDR1 2677G>T at exon 21, 3435C>T at exon 26 and their haplotypes with chemotherapy response of 54 Han Chinese patients with NSCLC.
|
18812689 |
2009 |
|
rs1045642
|
|
|
0.060 |
GeneticVariation |
BEFREE |
BRCA1 rs1799966 minor allele C (TC+CC vs. TT, OR = 0.402, 95% CI = 0.204-0.794, p = 0.008) and MDR1/ABCB1 rs1045642 minor allele A (GA +AA vs. GG, OR = 0.478, 95% CI = 0.244-0.934, p = 0.030) were associated with a better response to chemotherapy in advanced NSCLC patients.
|
24933103 |
2014 |